These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33483736)

  • 41. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
    Gupta R; Balzer B; Picken M; Osunkoya AO; Shet T; Alsabeh R; Luthringer D; Paner GP; Amin MB
    Am J Surg Pathol; 2009 Feb; 33(2):241-7. PubMed ID: 18941400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
    Brown AP; Courtney CL; Criswell KA; Holliman CL; Evering W; Jessen BA
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1091-101. PubMed ID: 18509643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway.
    Ito M; Yoshioka K; Akechi M; Yamashita S; Takamatsu N; Sugiyama K; Hibi M; Nakabeppu Y; Shiba T; Yamamoto KI
    Mol Cell Biol; 1999 Nov; 19(11):7539-48. PubMed ID: 10523642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1.
    Lisnock J; Griffin P; Calaycay J; Frantz B; Parsons J; O'Keefe SJ; LoGrasso P
    Biochemistry; 2000 Mar; 39(11):3141-8. PubMed ID: 10715136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pyrazolone based TGFbetaR1 kinase inhibitors.
    Guckian K; Carter MB; Lin EY; Choi M; Sun L; Boriack-Sjodin PA; Chuaqui C; Lane B; Cheung K; Ling L; Lee WC
    Bioorg Med Chem Lett; 2010 Jan; 20(1):326-9. PubMed ID: 19914068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTP Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS No. 106-99-0) in B6C3F1 Mice (Inhalation Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 May; 434():1-389. PubMed ID: 12616297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SCIO-469 Scios Inc.
    Nikas SN; Drosos AA
    Curr Opin Investig Drugs; 2004 Nov; 5(11):1205-12. PubMed ID: 15573872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing potency of c-Jun N-terminal kinase 3 (JNK3) inhibitors using 2D molecular descriptors and binary QSAR methodology.
    Ijjaali I; Petitet F; Dubus E; Barberan O; Michel A
    Bioorg Med Chem; 2007 Jun; 15(12):4256-64. PubMed ID: 17451961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
    Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
    J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain.
    Tong SE; Daniels SE; Black P; Chang S; Protter A; Desjardins PJ
    J Clin Pharmacol; 2012 May; 52(5):717-28. PubMed ID: 21659629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3.
    Christopher JA; Atkinson FL; Bax BD; Brown MJ; Champigny AC; Chuang TT; Jones EJ; Mosley JE; Musgrave JR
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2230-4. PubMed ID: 19303774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
    Ito K
    Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.